Company Overview

Conavi Medical Corp. is a Canadian medical technology company focused on cardiovascular imaging solutions used in interventional cardiology procedures. The company develops hybrid intravascular imaging systems that combine intravascular ultrasound (IVUS) and optical coherence tomography (OCT) technologies into a single platform intended to assist physicians in diagnosing and treating coronary artery disease. Conavi operates within the medical device, cardiovascular imaging, and interventional healthcare industries, with its primary commercial emphasis on imaging-guided percutaneous coronary intervention (PCI) procedures.

The company’s principal product platform has been the Novasight Hybrid System, designed to provide simultaneous structural and morphological imaging during minimally invasive cardiovascular procedures. Conavi’s revenue sources historically have included system sales, catheter sales, research collaborations, licensing activities, and development agreements. The company has targeted hospitals, catheterization laboratories, interventional cardiologists, and clinical research institutions, particularly in North America and selected international markets. Conavi traces its origins to technologies developed in Canada and evolved through research collaborations and commercialization efforts focused on improving procedural precision and clinical outcomes in coronary interventions.

Business Operations

Conavi Medical’s operations center on the development, commercialization, and clinical advancement of intravascular imaging technologies. The company’s core business activities include medical device engineering, software integration, imaging catheter development, regulatory compliance, and clinical validation. Its operational model has historically combined proprietary imaging technology development with strategic collaborations involving healthcare institutions and industry participants. Revenue generation has primarily depended on device commercialization, recurring disposable catheter sales, and development partnerships tied to imaging applications in cardiovascular care.

The company operates primarily from Canada while pursuing commercialization opportunities in the United States, Canada, and selected international healthcare markets. Conavi has maintained intellectual property related to hybrid imaging systems integrating IVUS and OCT modalities into a single imaging platform. The company has also engaged with manufacturing partners, clinical investigators, and regulatory bodies to support product development and adoption. Public disclosures and filings indicate that Conavi has pursued strategic collaborations to advance next-generation imaging systems and support clinical evidence generation in interventional cardiology.

Strategic Position & Investments

Conavi Medical’s strategic direction has focused on expanding the adoption of image-guided cardiovascular interventions and advancing hybrid imaging capabilities intended to improve procedural efficiency and diagnostic accuracy. A central component of the company’s strategy has been the continued refinement and commercialization of its hybrid imaging platform, including efforts to secure regulatory clearances, clinical validation, and broader physician adoption. The company has also pursued technology integration initiatives aimed at differentiating its imaging systems from standalone IVUS or OCT competitors.

In recent years, Conavi has emphasized partnerships and financing initiatives to support product commercialization and clinical development. Publicly available filings indicate strategic efforts to position the company within the broader structural heart and interventional cardiology ecosystem, particularly as hospitals increasingly adopt imaging-assisted PCI procedures. Conavi’s investment focus has included software-enabled imaging interpretation, catheter innovation, and clinical workflow integration. Data regarding large-scale acquisitions or extensive subsidiary portfolios remains limited in publicly available filings, and no major diversified operating subsidiaries have been prominently disclosed. Data inconclusive based on available public sources regarding material portfolio company holdings beyond core operating entities.

Geographic Footprint

Conavi Medical is headquartered in Toronto, Ontario, Canada, and has historically concentrated its operational and commercial activities in North America. The company’s regulatory and commercialization strategy has emphasized access to the United States cardiovascular device market due to its scale and concentration of interventional cardiology procedures. Clinical collaborations and commercialization discussions have also extended into select international markets where intravascular imaging adoption is growing.

Although Conavi is smaller in scale relative to multinational medical device competitors, its technologies have been positioned for use in global interventional cardiology markets. The company’s international presence has largely been driven through partnerships, distributor relationships, clinical collaborations, and regulatory engagement rather than extensive foreign operating infrastructure. Public disclosures indicate continued interest in expanding physician adoption and market penetration across regions where advanced imaging-guided cardiovascular procedures are becoming more prevalent.

Leadership & Governance

Conavi Medical has been led by executives with backgrounds in medical technology, cardiovascular imaging, healthcare commercialization, and corporate finance. The company’s leadership strategy has generally emphasized innovation in minimally invasive cardiovascular imaging, clinical collaboration, and disciplined commercialization within specialized medical device markets. Governance oversight has been provided through a board structure typical of publicly traded Canadian healthcare technology companies, with leadership focused on regulatory advancement, capital management, and strategic growth initiatives.

Key executives and leadership figures identified in public filings and company disclosures include:

• Thomas Looby – Chief Executive Officer
• Moe Khosravy – Chief Financial Officer
• Dr. Randy AuCoin – Chief Medical Officer
• Richard Wray – Chairman of the Board

Public statements from management have consistently emphasized advancing hybrid intravascular imaging technology, improving physician decision-making during coronary interventions, and building long-term shareholder value through clinical adoption and strategic partnerships.